| JOHN WAYNE CANCER INSTITUTE Patent applications |
| Patent application number | Title | Published |
|---|
| 20120088683 | Detection of Cancer Cells in Body Fluids - A method of detecting circulating melanoma or carcinoma cells in a subject. The method comprises obtaining a body fluid from a subject and detecting the expression of a panel of genes in the body fluid, wherein the expression of the panel of genes indicates the presence of circulating melanoma or carcinoma cells in the subject. Genes useful for detecting melanoma cells includes GalNAc-T, MAGE-A3, MART-1, PAX-3, and TRP-2; genes useful for detecting carcinoma cells include C-Met, MAGE-A3, Stanniocalcin-1, Stanniocalcin-2, mammaglobin, HSP27, GalNAc-T, CK20, and β-HCG. Also disclosed are kits containing agents for detecting the expression of these genes. | 04-12-2012 |
| 20110207136 | Detection of Micro Metastasis of Melanoma and Breast Cancer in Paraffin-Embedded Tumor Draining Lymph Nodes by Multimarker Quantitative RT-PCR - The invention provides a quantitative realtime RT-PCR assay for detection of metastatic breast, gastric, pancreas or colon cancer cells or metastatic melanoma. The assay allows to predict disease recurrence and survival in patients with AJCC stage I and II, and III disease using multimarker panels. The method for detecting metastatic melanoma cells utilizes panels of markers selected from a group consisting of MAGE-A3, GalNAcT, MART-1, PAX3, Mitf, TRP-2, and Tyrosinase. The method for detecting metastatic breast, gastric, pancreas or colon cancer cells in paraffin-embedded samples utilizes panels of markers selected from a group consisting of C-Met, MAGE-A3, Stanniocalcin-1, mammoglobin, HSP27, GalNAcT, CK20, and β-HCG. | 08-25-2011 |
| 20100304376 | Epigenetic Silencing of Cyclooxygenase-2 Affects Clinical Outcome in Gastric Cancer - The present invention discloses methods of using the methylation status of the COX-2 gene promoter region as a biomarker for a gastric cancer patient to determine a prognosis and a treatment regimen, and to monitor the progress of a treatment regimen. | 12-02-2010 |
| 20100227319 | USE OF RUNX3 AND MIR-532-5P AS CANCER MARKERS AND THERAPEUTIC TARGETS - The invention relates to methods for cancer diagnosis, prognosis, and treatment based on the expression or activity levels of RUNX3 and miR-532-5p. Also disclosed is a method of reducing the inhibition of RUNX3 by miR-532-5p with an agent that interferes with the interaction between RUNX3 and miR-532-5p transcripts. | 09-09-2010 |
| 20100003689 | Use of Methylation Status of MINT Loci as a Marker for Rectal Cancer - The invention relates to methods for predicting the outcome of rectal cancer and stratifying a rectal cancer treatment according to the level of DNA methylation at MINT 1, 3, 12, or 17. Also disclosed is a method of detecting rectal adenoma or malignancy based on the level of DNA methylation at MINT 2, 3, or 31. | 01-07-2010 |
| 20090280479 | USE OF FREE CIRCULATING DNA FOR DIAGNOSIS, PROGNOSIS, AND TREATMENT OF CANCER FUNDING - A method of detecting circulating DNA in a body fluid. The method comprises identifying a subject suffering from or at risk for developing cancer, obtaining a body fluid sample from the subject, and determining the sequence integrity of circulating DNA in the sample, wherein the circulating DNA is not purified from the sample. | 11-12-2009 |
| 20090263812 | USE OF ID4 FOR DIAGNOSIS AND TREATMENT OF CANCER - The invention relates to a method of determining whether a human subject is suffering from or at risk for developing pancreatic cancer by determining the methylation level of an ID4 gene promoter or the expression level of an ID4 gene in a biological sample from a human subject. Also disclosed are a method of analyzing the methylation level of an ID4 gene promoter or the expression level of an ID4 gene in a pancreatic cancer cell, and a method of inhibiting the methylation of an ID4 gene promoter or enhancing the expression of an ID4 gene by contacting a pancreatic cancer cell with a compound that decreases the methylation level of an ID4 gene promoter or increases the expression level of an ID4 gene in the cell. | 10-22-2009 |
| 20090220980 | USE OF METHYLATION STATUS OF MINT LOCI AND TUMOR-RELATED GENES AS A MARKER FOR MELANOMA AND BREAST CANCER - The invention relates to a method of detecting melanoma or breast cancer using DNA methylation in MINT17, MINT31, or the promoter region of WIF1, TFPI2, RASSF1A, SOCS1, GATA4, or RARβ2 as a biomarker. Also disclosed are methods of using the biomarker for determining the cancer status and predicting the outcome of the cancer. | 09-03-2009 |
| 20090208952 | UTILITY OF RET MUTANT IN DIAGNOSIS AND TREATMENT OF MELANOMA - The invention relates to a method of detecting a RET mutant in a melanoma cell. Also disclosed is a method of modulating the activity of a RET mutant in a melanoma cell with an agent that interferes with the activity of the RET mutant. | 08-20-2009 |
| 20090068660 | USE OF METHYLATED OR UNMETHYLATED LINE-1 DNA AS A CANCER MARKER - The invention relates to a method of detecting LINE-1 (long interspersed nucleotide elements-1) DNA either methylated or unmethylated at the promoter region in a tissue or body fluid sample from a subject. Also disclosed are methods of using LINE-1 DNA as a biomarker for diagnosing, predicting, and monitoring cancer progression and treatment. | 03-12-2009 |
| 20090061441 | EPIGENETIC SILENCING OF CYCLOOXYGENASE-2 AFFECTS CLINICAL OUTCOME IN GASTRIC CANCER - The present invention discloses methods of using the methylation status of the COX-2 gene promoter region as a biomarker for a gastric cancer patient to determine a prognosis and a treatment regimen, and to monitor the progress of a treatment regimen. | 03-05-2009 |
| 20090028866 | USE OF CCR9, CCL25/TECK, AND NITEGRIN alpha4 IN DIAGNOSIS AND TREATMENT OF MELANOMA METASTASIS IN THE SMALL INTESTINE - The invention relates to methods for determining whether a melanoma will metastasize or has metastasized to the small intestine in a subject by detecting or quantifying the expression of the CCR9, CCL25/TECK, or integrin α4 gene. Also disclosed are methods for treating subjects so identified. | 01-29-2009 |
| 20090011445 | METHOD AND APPARATUS FOR IN VIVO COLLECTION OF CIRCULATING BIOLOGICAL COMPONENTS - The invention relates generally to in vivo collection of circulating molecules, tumor cells and other biological markers using a collecting probe. The probe is configured for placement within a living organism for an extended period of time to provide sufficient yield of biological marker for analysis. In some embodiments of the invention, active attraction of biological markers are provided. A partial or complete analytic/detection assembly may also be integrated with the probe. | 01-08-2009 |
| 20090011418 | FUNCTIONAL TOLL-LIKE RECEPTORS (TLR) ON MELANOCYTES AND MELANOMA CELLS AND USES THEREOF - The invention relates to a method of detecting Toll-like receptor (TLR) gene expression or protein activity in a melanocyte or melanoma cell. Also disclosed are a method of modulating TLR gene expression or protein activity in a melanocyte or melanoma cell by contacting the cell with a TLR modulating agent and a method of inhibiting melanoma cell migration (e.g., spreading) by contacting the cell with a TLR inhibitor. | 01-08-2009 |
| 20080299551 | METHYLATION OF ESTROGEN RECEPTOR ALPHA AND USES THEREOF - Methods for diagnosis, prognosis, and treatment of cancer based on the methylation status of the ER-α gene promoter are disclosed. Methylation of the ER-α gene promoter is indicative of cancer and unfavorable prognosis. The cancer can be treated with a demethylation agent. | 12-04-2008 |
| 20080268449 | UTILITY OF B-RAF DNA MUTATION IN DIAGNOSIS AND TREATMENT OF CANCER - The present invention discloses a method of detecting a wild-type or mutant B-RAF gene in a body fluid sample from a subject. Also disclosed are methods of using B-RAF as a biomarker for detecting cancer, predicting the outcome of cancer, and monitoring the treatment of cancer or the status of cancer. Furthermore, the invention discloses methods and compositions for detecting a mutant gene with a peptide nucleic acid clamp capable of hybridizing to a wild-type gene and a locked nucleic acid probe capable of hybridizing to a mutant of the gene. | 10-30-2008 |
| 20080241847 | METHOD AND APPARATUS FOR IN VIVO SURVEILLANCE OF CIRCULATING BIOLOGICAL COMPONENTS - The invention relates generally to in vivo collection of circulating molecules, tumor cells and other biological markers using a collecting probe. The probe is configured for placement within a living organism for an extended period of time to provide sufficient yield of biological marker for analysis. | 10-02-2008 |
